The Patent Finder
US

Method of Treatment Using Nanoparticulate Ganaxolone Formulations

US 11,071,740 In force
OverviewFamilyAssignmentsSources & methods

Term ends Nov 28, 2026 · Medium confidence

Filed Oct 2, 2018 as application 16/149,970 · Granted Jul 27, 2021
Base term, 20 years from filing
Today
20 years from filing
2006 2026
Clock starts
Nov 28, 2006
Term ends
Nov 28, 2026
Granted
Jul 27, 2021
base term fee events Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,858,609, US 8,022,054, US 8,318,714, US 8,367,651, US 8,618,087, US 9,029,355, US 9,056,116, US 9,452,176, to Nov 28, 2026. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 1 maintenance fees is paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Nov 28, 2006, when application 11/605,700, the earliest non-provisional in its chain, was filed (this one was filed Oct 2, 2018); a parent in its chain could not be resolved (the next row)Nov 28, 2026High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,858,609, US 8,022,054, US 8,318,714, US 8,367,651, US 8,618,087, US 9,029,355, US 9,056,116, US 9,452,176)resolves to Nov 28, 2026, no earlier than this term, so no changeMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 1 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderNov 28, 2026Medium confidence

This family

US 8,022,054In force
no later than Nov 2027
no later than Nov 2027
US 8,367,651In force
Nov 2026
Nov 2026
US 8,318,714In force
Nov 2031
Nov 2031
US 9,056,116In force
no later than Nov 2026
no later than Nov 2026
US 8,618,087In force
no later than Nov 2026
no later than Nov 2026
US 9,029,355In force
Nov 2026
Nov 2026
US 9,452,176In force
Nov 2026
Nov 2026
US 11,071,740this patent
Nov 2026
Nov 2026
8 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
May 11, 2021
Reel 56206, frame 266
Marinus Pharmaceuticals, Inc.Oaktree Fund Administration, LLCSecurity Interest
Jun 21, 2021
Reel 56608, frame 740
Shaw, Kenneth; Zhang, MingbaoMarinus Pharmaceuticals, Inc.Assignment of Assignor's Interest
Oct 28, 2022
Reel 61580, frame 171
Marinus Pharmaceuticals, Inc.Sagard Healthcare Royalty Partners, LPSecurity Interest
Feb 13, 2025
Reel 70204, frame 35
Sagard Healthcare Partners Funding Company SPE 1, LLCMarinus Pharmaceuticals, Inc.Release of Security Interest
Feb 20, 2025
Reel 70278, frame 496
Oaktree Fund Administration, LLCMarinus Pharmaceuticals, Inc.Release of Security Interest
May 15, 2025
Reel 71128, frame 703
Marinus Pharmaceuticals, Inc.Immedica Pharma US Inc.Change of Name

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited